(MENAFN- Ameliorate Digital Consultancy)
Selbyville, Delaware: Global Market Insights Inc., announces a report on Sleep Disorder Market Trends & Forecast – 2027.' The study encompasses an elaborate analysis of the product, application, and regional trends in the industry.
“Global sleep disorder industry size projected to be valued at $20.6 billion by 2027, suggests a Global Market Insights, Inc. report”
Sleep disorder market is likely to gain significant profits in the coming years. The onslaught of COVID-19 has been anything but positive, permanently affecting sphere of human life. According to the researchers, those with obstructive sleep apnea and other breathing disorders that cause oxygen levels to decrease during sleep are at a higher risk of severe sickness from COVID-19.
To access a sample copy or view the Sleep Disorder Market report in detail along with the table of contents, please click the link below:
According to a recent study involving COVID-19 positive and COVID-19 negative individuals, those with a positive test result were 41% more likely to be diagnosed with sleep disorders, as well as 61% more inclined toward the use of sleep medication of some kind.
Even before the onset of the pandemic, the sleeping patterns of individuals worldwide had been changing. A 2019 report by Raconteur, a content marketing agency, states that nearly 62% of the global adult population reported having poor sleep quality.
One of the most prominent factors driving sleep disorder market growth in recent years is the growing prevalence of chronic ailments. More than 50 million Americans suffer from chronic sleep disorders, out of which, insomnia and obstructive sleep apnea are the two most prevalent, involving about 10 to 30% of the population.
Insomnia: A growing concern for many
Insomnia is defined as a condition in which the person has difficulties in sleeping or staying asleep, which causes exhaustion, difficulty focusing, and irritation. According to psychiartry.org, around one-third of individuals suffer insomnia symptoms, with 6-10% meeting the criteria for insomnia disorder. According to another study by Flinders University researchers, those who have both insomnia and obstructive sleep apnea are more likely to have cardiac issues.
Companies are at work to cater to the growing market demand. In September 2021, Asahi Kasei unit ZOLL Medical entered into an agreement to acquire medical device and digital health business, Itamar Medical. Itamar manufactures non-invasive medical equipment and solutions for the diagnosis of respiratory and sleep diseases.
The WatchPAT Home Sleep Apnea Device was created by the firm to help with the diagnosis of sleep apnea. The U.S. Food and Drug Administration (FDA) has approved the product for use as a home-based testing option for sleep disorders. According to ZOLL Medical, OSA is associated with an increased risk of developing and progressing coronary heart disease, heart failure, stroke, and atrial fibrillation.
Rising cases of sleep apnea
According to my.clevelandclinic.org, sleep apnea may affect people of all ages, including newborns and children, although it is more common in adults over 50 and those who are overweight. If left untreated, it can lead to major health issues such as high blood pressure and cardiac difficulties. As leading companies strive hard to combat the rising cases of sleep apnea, product innovations, along with other marketing tactics have proven to be pivotal.
Somnics Inc, a medical equipment expert in sleep breathing problems, unveiled iNAP in 2021, a novel oral negative pressure device for the treatment of adult obstructive sleep apnea. The technology employs a mouthpiece with thin tubing, and a small, battery-powered console the size of a smartphone to apply a gentle, oral suction during sleep, allowing the airway to remain open while breathing normally via the nose.
Sleep disorder therapy gains prominence
The demand for therapeutics is increasing, due to an increase in the number of persons suffering from cognitive sleep disorders. To cater the growing demand, Idorsia (IDIA.S), a Swiss pharmaceutical company, announced U.S. FDA approval for its adult insomnia therapy, in January 2022. The medicine, to be marketed as Quviviq, demonstrated clinically relevant improvements in nighttime sleep and daytime functioning during trails, over a sustained period.
A growing number of emerging medical-technology companies are joining larger corporate players to tap into the market potential. Astellas Pharma Inc, Cardinal Health, Cadwell Laboratories Inc., Compumedics Limited, Ferring International Center SA, GlaxoSmithKline plc, Koninklijke Philips N.V., and ResMed Inc. are listed amongst the top companies offering sleep disorder diagnosis and treatment products globally.
Partial Table of Contents (ToC) of the Sleep Disorder Market report:
Chapter 4 Sleep Disorder Market, By Disorder Type
4.1 Key segment trends
4.2 Sleep apnea
4.2.1 Market size, by region, 2016 – 2027 (USD Million)
4.2.2 Obstructive sleep apnea
4.2.2.1 Market size, by region, 2016 – 2027 (USD Million)
4.2.3 Central sleep apnea
4.2.3.1 Market size, by region, 2016 – 2027 (USD Million)
Chapter 5 Sleep Disorder Market, By Product
5.1 Key segment trends
5.2 Diagnostics
5.2.1 Market size, by region, 2016 – 2027 (USD Million)
5.2.2 Actigraphy systems
5.2.2.1 Market size, by region, 2016 – 2027 (USD Million)
5.2.3 Polysomnography (PSG) device
5.2.3.1 Market size, by region, 2016 – 2027 (USD Million)
Browse complete table of content of this report @
About Global Market Insights
Global Market Insights Inc., headquartered in Delaware, U.S., is a global market research and consulting service provider; offering syndicated and custom research reports along with growth consulting services. Our business intelligence and industry research reports offer clients with penetrative insights and actionable market data specially designed and presented to aid strategic decision making. These exhaustive reports are designed via a proprietary research methodology and are available for key industries such as chemicals, advanced materials, technology, renewable energy and biotechnology.
MENAFN05082022004660010643ID1104652497